Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Harter

Showing results (51-60 of 276) with videos related to

Pageof 28
Sort By:
Advances in Therapy|September 4, 2012
Bevacizumab in the treatment of ovarian cancerFlorian Heitz, Philipp Harter, Jana Barinoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activityFlorian Heitz, Andreas du Bois, Justine Rochon, et al.
Gynecologic Oncology|July 13, 2015
Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgeryBeyhan Ataseven, Andreas du Bois, Alexander Reinthaller, et al.
Journal of the American Academy of Dermatology|January 18, 2014
Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy NetworkAlexander Luyten, Philipp Sörgel, Andreas Clad, et al.
Gynecologic Oncology|May 22, 2016
The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?Beyhan Ataseven, Philipp Harter, Christoph Grimm, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 30, 2019
Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case seriesEnzo Ricciardi, Helmut Plett, Valentina Sangiorgio, et al.
Gynecologic Oncology|March 26, 2019
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 yearsThorsten Heilmann, Jacobus Pfisterer, Antje Marie Hempel, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2009
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastasesFlorian Heitz, Philipp Harter, Hans-Joachim Lueck, et al.
Gynecologic Oncology|February 4, 2018
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trialChristoph Grimm, Stephan Polterauer, Samir Helmy-Bader, et al.
Gynecologic Oncology|November 20, 2016
Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancerFlorian Heitz, Alexandra Hengsbach, Philipp Harter, et al.
Pageof 28

Showing results (51-60 of 276) with videos related to

Sort By:
Pageof 28
Advances in Therapy|September 4, 2012
Bevacizumab in the treatment of ovarian cancerFlorian Heitz, Philipp Harter, Jana Barinoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activityFlorian Heitz, Andreas du Bois, Justine Rochon, et al.
Gynecologic Oncology|July 13, 2015
Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgeryBeyhan Ataseven, Andreas du Bois, Alexander Reinthaller, et al.
Journal of the American Academy of Dermatology|January 18, 2014
Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy NetworkAlexander Luyten, Philipp Sörgel, Andreas Clad, et al.
Gynecologic Oncology|May 22, 2016
The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?Beyhan Ataseven, Philipp Harter, Christoph Grimm, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 30, 2019
Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case seriesEnzo Ricciardi, Helmut Plett, Valentina Sangiorgio, et al.
Gynecologic Oncology|March 26, 2019
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 yearsThorsten Heilmann, Jacobus Pfisterer, Antje Marie Hempel, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2009
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastasesFlorian Heitz, Philipp Harter, Hans-Joachim Lueck, et al.
Gynecologic Oncology|February 4, 2018
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trialChristoph Grimm, Stephan Polterauer, Samir Helmy-Bader, et al.
Gynecologic Oncology|November 20, 2016
Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancerFlorian Heitz, Alexandra Hengsbach, Philipp Harter, et al.
Pageof 28